TLR4 and dilated cardiomyopathy: In another study, dapagliflozin treatment was shown to elicit positive effects on doxorubucin-induced dilated cardiomyopathy by inhibiting NLRP3 inflammasome, decreasing p38-dependent toll-like receptor 4 (TLR4) expression [65].